Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-PD analysis of sugammadex reversal of rocuronium-induced neuromuscular blockade in children under 2 years
KCT0010940Phase 3
Key facts
- Status
- Recruiting
- Start
- Nov 2025
- Countries
- 1
- Sponsor
- Ministry of Health & Welfare
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Drugs
- Sugammadex
- Conditions
- neuromuscular block (NMB)
01
Overview
Phase 3, single-arm trial of Sugammadex in neuromuscular block (NMB), sponsored by Ministry of Health & Welfare. Started Nov 2025; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedSingle group
Sugammadex conventional reversal
Children under 2 years receiving sugammadex to reverse rocuronium-induced neuromuscular blockade during surgery, with PK-PD assessments.
03
Who it enrols
Children younger than 2 years of age in Korea undergoing surgery requiring rocuronium-induced neuromuscular blockade and reversal with sugammadex, with intraoperative monitoring.
Beyond the preview
Go deeper on KCT0010940.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010940.